Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

BeOne Medicines Q3 Revenue Hits $1.89 Billion as Net Income Climbs 208%

BeOne Medicines Ltd. delivered significant growth in the third quarter of 2026, characterized by a 33.9% revenue increase and a sharp rise in net income. The company raised its full-year 2026 guidance following strong product sales and improved operating leverage.

Flasks, erlenmeyer, chemistry, laboratory. Stock photo illustrating BeOne Medicines' financial results story.
BeOne Medicines Ltd. · Photo: Republica / Pixabay
Results at a glance · $ Million
Metric Q3-26Q3-25
Revenue 1,8901,412
Gross Profit 1,6731,216
Pretax Income 410.36147.16
Net Income 384.71124.84
Diluted EPS 0.250.08
Net Income YoY
+208.2%

Key highlights

  • Quarterly revenue rose to $1,890 million, up from $1,412 million in the prior year
  • Net income surged 208.2% year-over-year to reach $384.71 million
  • Gross profit margins expanded to 88.5% compared to 86.1% in Q3 2025
  • Full-year 2026 revenue guidance was raised to a range of $6.9 billion to $7.0 billion
  • Diluted earnings per share increased to $0.25 from $0.08 in the year-ago period

How the Period Went

BeOne Medicines Ltd. achieved a substantial increase in financial performance during the third quarter of 2026. Total revenue reached $1,890 million, representing a 33.9% increase from the $1,412 million reported in the same period of 2025. This top-line growth translated into significant bottom-line gains, as net income rose 208.2% to $384.71 million, compared to $124.84 million in the prior year. Diluted earnings per share followed this upward trajectory, climbing to $0.25 from $0.08. The results indicate a period of rapid scaling, with revenue gains significantly outpacing the prior year's comparative figures.

Margins and Profitability

Profitability metrics for the quarter show enhanced operational efficiency. Gross profit climbed to $1,673 million from $1,216 million, resulting in an improved gross margin of 88.5% compared to 86.1% in Q3 2025. Pretax income saw a sharp rise to $410.36 million from $147.16 million, reflecting improved operating leverage as the company managed increased spending in research and development alongside selling, general, and administrative expenses. This expansion in margins suggests that BeOne Medicines is successfully converting a higher proportion of its product sales into net earnings as its commercial infrastructure and market reach continue to mature.

Business Overview

BeOne Medicines is a biopharmaceutical entity focused on the development and commercialization of innovative oncology treatments. The company serves global markets, providing specialized therapies for hematological malignancies and solid tumors. Its business model relies on a robust pipeline of late-stage clinical candidates, supported by a growing commercial portfolio that drives the majority of its $1.89 billion quarterly revenue. The company recently focused on securing regulatory milestones and expanding its market share in the competitive oncology sector, utilizing an integrated commercial platform to reach healthcare providers and institutional pharmacy networks across several key international markets.

Financial Context

  • Quarterly revenue has grown sequentially from $1.51 billion in Q1 2026 to $1.89 billion in Q3 2026 according to SEC filings
  • Management raised full-year 2026 revenue guidance on November 5, 2026, to a new range of $6.9 billion to $7.0 billion
  • Full-year GAAP operating income is now projected to fall between $1,200 million and $1,300 million per stocktitan.net
  • The company maintained a 33.9% year-over-year revenue growth rate, an acceleration from previous fiscal periods
  • Profitability has been bolstered by strong product sales volume despite elevated R&D investment for late-stage trials

Industry Landscape

The oncology sector is currently characterized by high demand for targeted therapies and accelerated regulatory cycles. BeOne Medicines’ growth occurs as the industry shifts toward personalized medicine and next-generation inhibitors. The company is positioned against major biopharmaceutical peers competing for dominant shares in the hematology market. A critical upcoming milestone for the firm is the presentation of Phase 3 MANGROVE study data at the 68th ASH Annual Meeting on December 13, 2026. This follows the U.S. FDA’s decision on November 4, 2026, to grant a Priority Review for the company's latest regulatory submission, a status typically reserved for drugs offering significant improvements in treatment.

Recent quarters and guidance
DateAnnouncementAmount
05 Aug 2026Q2 2026 total revenue and raised FY 2026 guidanceSource: SEC filing$1.71 Billion
06 May 2026Q1 2026 total revenue and raised FY 2026 guidanceSource: businesswire.com$1.51 Billion
26 Feb 2026Q4 2025 total revenue and FY 2026 guidanceSource: SEC filing$1.50 Billion
06 Nov 2025Q3 2025 total revenue and FY 2025 guidanceSource: SEC filing$1.41 Billion
06 Aug 2025Q2 2025 total revenue and updated FY 2025 guidanceSource: nasdaq.com$1.32 Billion
Source verified

SEC filing by BeOne Medicines Ltd. announcing its financial results for the quarter ended September 30, 2026.

Read the filing ↗

Track BeOne Medicines Ltd. live

Get the next BeOne Medicines Ltd. SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.